Please assess the completion status of the following clinical trial:

Trial Title: SALT Trial Study of Ascending Levels of Tolvaptan in Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Hyponatremia in euvolemic or hypervolemic states, defined as serum sodium \<135 mEq/L prior to randomization.~* Able to give Informed Consent~Exclusion Criteria~* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods~* Hyponatremia in hypovolemic states.~* Acute and transient hyponatremia associated with head trauma or post-operative state.~* Hyponatremia due to uncontrolled hypothyroidism or uncontrolled adrenal insufficiency.~* Cardiac surgery within 30 days of potential study enrollment, excluding percutaneous coronary interventions.~* History of a myocardial infarction within 30 days of potential study enrollment.~* History of sustained ventricular tachycardia or ventricular fibrillation within 30 days, unless in the presence of an automatic implantable cardioverter defibrillator.~* Severe angina including angina at rest or at slight exertion and/or unstable angina.~* History of a cerebrovascular accident within the last 30 days. 10) Subjects with psychogenic polydipsia may not be included, however subjects with other psychiatric illness may be included.~* Systolic arterial blood pressure \<90 mmHg.~* History of hypersensitivity and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril).~* History of drug or medication abuse within the past year,or current alcohol abuse.~* Uncontrolled diabetes mellitus defined as fasting glucose \>300mg/dL.~* Urinary tract obstruction except BPH if non-obstructive.~* Previous participation in another clinical drug trial within the past 30 days.~* Previous participation in this or any other tolvaptan clinical trial.~* Terminally ill or moribund condition with little chance of short term survival.~* Serum creatinine \>3.5 mg/dL.~* Serum sodium \<120 mEq/L with associated neurologic impairment, i.e. symptoms such as apathy, confusion, seizures.~* Patients with progressive or episodic neurologic disease such as multiple sclerosis or history of multiple strokes.~* Child-Pugh score greater than 10 (unless approved)~* Patients receiving intravenous fluids at a rate greater than KVO (Keep Vein Open).~* Hyponatremia due to lab artifacts~* Patients receiving AVP or its analogs for treatment of any condition.~* Patients receiving within 7 days of randomization, other medications for treatment of hyponatremia specifically: demeclocycline, lithium carbonate or urea~* Patients likely requiring IV saline for correction of symptomatic or asymptomatic severe hyponatremia during the course of the study.~* Severe pulmonary artery hypertension~* Hyponatremia should not be the result of any medication that can safely be withdrawn

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).